Management of secondary hyperparathyroidism in Italy: Results of the Italian FARO survey

Journal of Nephrology

Volumn 24, Issue 2, 2011, Pages 225-235

  Mazzaferro, Sandro ^a   Brancaccio, Diego ^b   Messa, Piergiorgio ^c   Andreucci, Vittorio E ^d   Bellinghieri, Guido ^e   Bigazzi, Roberto ^f   Bolasco, Piergiorgio ^f   Costanzo, Anna Maria ^g   Paparatti, Umberto di Luzio ^g   Cannella, Giuseppe ^h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e G Martino Hospital   (Italy)

^f Spedali Riuniti ^*  (Italy)

^g ABBOTT DIAGNOSTICS   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

Author keywords

Calcimimetics; Calcitriol; K DOQI; Paricalcitol; Secondary hyperparathyroidism

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE;

AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HEALTH SURVEY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; REFERENCE VALUE; SECONDARY HYPERPARATHYROIDISM;

AGED; CALCIMIMETIC AGENTS; CALCIUM; CHRONIC DISEASE; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; ITALY; KIDNEY DISEASES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN D;

EID: 79953710538     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2010.6193     Document Type: Article

References (16)

1. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006;70:351-357.
2. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
4. Tentori F. Focus on vitamin D therapy in chronic kidney disease. J Nephrol. 2007;20:511-514.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-S202.
6. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopulos DG. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol. 2006;38:739-743.
7. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:34-38.
8. Al Aly Z, Gonzalez EA, Martin KJ, Gellens ME. Achieving K/ DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol. 2004;24:422-426.
9. Brancaccio D, Cozzolino M, Galassi A, et al. Management of secondary hyperparathyroidism in uremic patients: the role of new vitamin D analogs. J Nephrol. 2007;20:3-9.
10. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793-1800.
11. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438-441.
12. Capuano A, Serio V, Pota A, Memoli B, Andreucci V. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol. 2009;22:59-68.
13. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
14. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519-530.
15. St Peter WL, Li Q, Liu J, et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol. 2009;4:354-360.
16. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):S1-130.